B. Metzler seel. Sohn & Co. Holding AG bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 19,367 shares of the medical equipment provider's stock, valued at approximately $2,126,000.
Several other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its position in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after buying an additional 208 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 92 shares in the last quarter. Nkcfo LLC bought a new stake in shares of Lantheus during the 2nd quarter valued at about $47,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new position in shares of Lantheus in the third quarter worth approximately $51,000. 99.06% of the stock is owned by institutional investors.
Shares of Lantheus stock opened at $87.32 on Friday. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The business's 50 day simple moving average is $103.76 and its two-hundred day simple moving average is $96.59. The stock has a market capitalization of $6.07 billion, a P/E ratio of 14.53 and a beta of 0.51.
LNTH has been the subject of a number of research reports. Truist Financial reissued a "buy" rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday. JMP Securities lowered their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Finally, B. Riley raised their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $122.50.
Check Out Our Latest Analysis on Lantheus
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.